Anzeige
Mehr »
Login
Montag, 22.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Der KI-Boom ist vorbei! Aber dieser heiße Sektor verspricht, weiter zu wachsen...
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P9YT | ISIN: ES0169501022 | Ticker-Symbol: PMRA
Stuttgart
22.04.24
08:02 Uhr
25,940 Euro
0,000
0,00 %
1-Jahres-Chart
PHARMA MAR SA Chart 1 Jahr
5-Tage-Chart
PHARMA MAR SA 5-Tage-Chart
RealtimeGeldBriefZeit
26,56026,62015:31
26,46026,76015:28

Aktuelle News zur PHARMAMAR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08.04.PHARMA MAR, S.A.: EthiFinance Ratings maintains long-term credit rating of Pharma Mar.2
05.04.PHARMA MAR, S.A.: The Company reports details of the operations of the Liquidity Agreement between 01/02/2024 and 31/03/20241
04.04.PHARMA MAR, S.A.: The Executive Committee of Pharma Mar, S.A. has decided to implement the Stock Ownership Plan approved by resolution of the General Shareholders' Meeting of 31 May 2023.2
28.02.PHARMA MAR, S.A.: The Company reports draw up of the Annual Financial Statements 2023, a proposal for a dividend, and a conference call with analysts and investors.8
28.02.PHARMA MAR, S.A.: The Company sends press release regarding year 2023 results together with financial report.7
28.02.PHARMA MAR, S.A.: FY2023 release of results6
31.01.PHARMA MAR, S.A.: The Company reports on treasury share acquisitions in the period from January 1 to January 31, 2024. Ending of the Acquisition of Treasury Shares and resumption of the liquidity contract.4
30.01.PHARMA MAR, S.A.: The Company informs of changes in the chairmanship of the Appointments and Compensation and Sustainability Committee.3
08.01.PHARMA MAR, S.A.: The Company reports on treasury share acquisitions in the period from December 1 to December 31, 2023.2
18.12.23PHARMA MAR, S.A.: Sylentis, a subsidiary of Pharma Mar, announces that the FYDES study to evaluate the safety of tivanisiran in patients with dry eye disease has met its primary endpoint.9
12.12.23PHARMA MAR, S.A.: The Company announces that its partner Luye Pharma Group Ltd has received approval for commercialization for Zepzelca® (lurbinectedina) in Hong Kong.9
05.12.23PHARMA MAR, S.A.: The Company reports on treasury share acquisitions in the period from November 1 to November 30, 2023.2
04.12.23PHARMA MAR, S.A.: The Company announces that its partner Luye Pharma Group Ltd has received approval for commercialization for Zepzelca® (lurbinectedina) in Macao.7
07.11.23PHARMA MAR, S.A.: The Company announces that its partner Adium Pharma has received approval for commercialization for Zepzelca® (lurbinectedina) in Peru.7
06.11.23PHARMA MAR, S.A.: The Company reports on treasury share acquisitions in the period from October 1 to October 31, 20234
06.11.23PHARMA MAR, S.A.: The Company announces a US$10 million milestone payment from Janssen Products LP10
31.10.23PHARMA MAR, S.A.: Pharma Mar initiates a Phase IIb/III clinical trial of Zepzelca® (lurbinectedin) for the treatment of patients with metastatic Leiomyosarcoma14
26.10.23PHARMA MAR, S.A.: The Company files third quarter 2023 financial information and announces a conference call with analysts and investors.3
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1